Novel injectable bispecific antibody epcoritamab approved in EU and UK for advanced lymphoma
Hospital Pharmacy Europe
OCTOBER 23, 2023
It is designed to simultaneously bind to both the cluster of differentiation (CD)3 proteins on immune T cells and the CD20 proteins on cancerous B cells and activate the T cell to destroy the B cell. The primary endpoint was overall response rate determined by the 2014 Lugano criteria as assessed by an independent review committee.
Let's personalize your content